Quite possibly. I don't understand the difference between P's MOA and the mAB's. I know a lot of the drugs with the ...imab or ...umab suffix have some pretty bad side effects. I do know that the BI drug is showing some fairly good efficacy. Maybe that's a good sign for P. I don't know what the difference is between targeting IL-23 vs. IL-20.
P's advantages still remain (low/no side effects, cheap to make, oral treatment).
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links